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INTRODUCTION
Cerebrotendinous xanthomatosis is a rare autosomal
recessive hereditary disease that is caused by a mutation
in the gene encoding the mitochondrial enzyme sterol 27-
hydroxylase (CYP27). The CYP27 gene is located on
chromosome 2q35-qter and is responsible for the conversion
of cholesterol into cholic and chenodeoxycholic acid.
Cerebrotendinous xanthomatosis results in increased levels
of serum cholestanol, a cholesterol precursor, and increased
deposition of cholestanol and cholesterol in various tissues,
especially the lenses, tendons, and the central nervous
system. The principal manifestations of Cerebrotendinous
xanthomatosis include juvenile cataracts, tendon xantho-
mas, and progressive neurological symptoms.
1
Early recognition of this condition is essential because
cholic and chenodeoxycholic acid replacement therapy can
prevent Cerebrotendinous xanthomatosis -induced brain
damage, which leads to severe neurological dysfunction
and death. We present the case of a patient with clinical,
radiological, and biochemical evidence of Cerebrotendinous
xanthomatosis and his response to cholic and chenodeoxy-
cholic acid treatment.
CASE REPORT
This report describes a 30-year-old male who displayed
normal psychomotor development until 10 years of age
when, according to his mother, he began presenting
learning difficulties and showed progressive cognitive
decline. At 15 years of age, the patient presented progres-
sive gait instability and enlargement of the Achilles tendons.
At age 17, he suffered his first convulsive episode. The
patient has suffered a total of four seizures since that time,
and his seizure condition is adequately controlled with the
use of anticonvulsants. A family history revealed that the
patient’s parents were cousins. Physical examination
revealed bilateral Achilles tendon enlargement and bilateral
cataracts. A neurological examination identified spastic
paraparesis, brisk deep tendon reflexes and extensor plantar
responses, upper limb symmetrical dysmetria and dysdia-
dochokinesia, and ataxic-paraparetic gait. The remainder of
the patient’s physical examination was normal.
Magnetic resonance imaging (MRI) of the patient’s skull
revealed mild cerebellar atrophy (Figure 1). MRI of the left
ankle showed fusiform thickening of the Achilles tendon
with heterogeneous signals on all sequences, T2-hyperin-
tense foci due to the presence of fat, and a slight increase in
the uptake of paramagnetic contrast. These results were
suggestive of a xanthoma of the Achilles tendon (Figure 2).
Laboratory tests (complete blood count, biochemistry, liver
and kidney function, lipid panel, and coagulation tests)
were normal. The patient’s serum cholestanol level was high
(28.3 mg/mL, normal value ,6 mg/mL).
Based on these findings, the patient was diagnosed with
CTX, and treatment with CDCA (750 mg/day) was imme-
diately initiated. The drug was imported from Germany.
A significant improvement in neurological symptoms was
observed after one year of follow-up, especially with respect
to ataxia and coordination. The patient retains a slightly
ataxic gait but presents normal finger-to-nose and fast finger
movements, and his serum cholestanol level has been
reduced to 4.1 mg/mL. In addition, the patient has under-
gone eye surgery to treat his cataracts. The patient
authorized the publication of this case report by signing a
consent form.
DISCUSSION
Van Bogaert et al. described the first CTX phenotype in
1937.
2 Subsequent work established several additional
symptoms of CTX, including cholestanol accumulation in
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Figure 1 - Brain MRI sagittal section in T1, showing mild
cerebellar atrophy in a patient with CTX.
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1217several tissues and the absence of CDCA in the bile. These
symptoms were determined to be the result of a disorder of
hepatic conversion of cholesterol to cholic acid and CDCA.
3
In 1975, Salen et al. reported that administration of CDCA
dramatically reduced cholestanol synthesis in CTX
patients.
4 In 1984, Berginer et al. demonstrated that one
year of CDCA oral supplementation treatment at 750 mg/
day was sufficient to produce a significant improvement in
neurological symptoms, normalization of EEG readings,
and a reduction in serum cholestanol in CTX patients.
5 In
1991, Cali et al. identified a defect in the gene encoding the
27-hydroxylase enzyme in CTX patients.
6 More than fifty
different mutations of this gene have since been reported
worldwide, and molecular analysis has enabled diagnosis
during the pre-symptomatic period.
7
The unexplained presence of bilateral cataracts and
chronic diarrhea in children suggests a diagnosis of CTX.
Tendon xanthomas usually appear in the second or third
decade of life, especially in the Achilles tendons. Neuro-
logical symptoms usually begin in the second decade of life
and include ataxia, pyramidal and extrapyramidal signs,
peripheral sensory-motor neuropathy, epilepsy, and
dementia.
7,8 Psychiatric manifestations such as depression,
suicidal thoughts, catatonia, and psychotic symptoms may
also present with CTX and usually appear at early stages.
9
Other clinical manifestations include osteoporosis, bone
fractures, premature arteriosclerosis, and coronary and lung
disease.
1,8
The mechanism underlying the progressive neurological
dysfunction in CTX remains unknown. Some authors
support the hypothesis that increased concentrations of
apolipoprotein B in the cerebrospinal fluid (CSF) of CTX
patients facilitates cholestanol and cholesterol transport
across the blood-brain barrier. Presumably, this accumula-
tion of cholestanol activates apoptotic pathways, resulting
in neuronal death. However, CDCA treatment restores the
selective permeability of the blood-brain barrier, normal-
izing the concentration of sterols and lipoproteins in the CSF
and promoting reversal of the neurological symptoms.
1,10
In a recent study, Berginer et al. demonstrated that early
diagnosis and initiation of CDCA treatment during the
pre-clinical and initial phases of CTX may prevent the
development of clinical manifestations of CTX. These
authors suggest that the following three steps are funda-
mental to prevent irreversible damage in patients with CTX:
1) recognition of early symptoms, including chronic
diarrhea and juvenile cataracts, by pediatricians, 2) con-
firmation of the diagnosis through biochemical and genetic
analysis, and 3) immediate CDCA treatment to prevent the
CTX phenotype.
7
This report describes the case of a patient with clinical,
biochemical, and radiological characteristics indicative of
CTX. In support of this diagnosis, biochemical analysis
demonstrated elevated cholestanol levels. Tendon xantho-
mas can occur in other lipidoses, such as familial hyperch-
olesterolemia and sitosterolemia, but juvenile cataracts and
progressive neurological symptoms are only seen in CTX.
1
We were unable to perform molecular genetic analysis in
our patient, but MRI analysis of the skull revealed cerebellar
atrophy. A similar finding has been reported by other
authors, as have bilateral and symmetric hyperintense
lesions surrounding the white matter of the dentate nuclei,
cerebral atrophy, and demyelinating lesions.
11 These
changes were not demonstrated in our case due to techno-
logical limitations. CDCA treatment was immediately
initiated in our patient, and a significant improvement in
neurological symptoms was observed after one year of
treatment. Furthermore, the clinical improvement correlated
with a reduction in cholestanol serum levels. Unfortunately,
because treatment was initiated at a late stage in this case, it
did not result in a functional cure of CTX. However, the
treatment did promote a significant improvement in quality
of life and, more importantly, prevented progression of the
disease.
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Figure 2 - Ankle MRI sagittal section in T1 showing Xanthoma of
the Achilles in a patient with CTX.
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